Company intelligence / Profile preview

Nutcracker Therapeutics

Emeryville, California, United Statesnutcrackerx.com ↗

Ownership: Private
Employees: ~134
Development stage: Preclinical

Overview

Nutcracker Therapeutics has demonstrated preclinical anti-tumor activity for two mRNA drug candidates—NTX-471 targeting CD47 and NTX-250 targeting HPV-driven tumors. Both programs have shown promising results in animal models but have not yet entered clinical trials as of the latest public disclosures.

Therapeutic areas: Oncology
Modalities: mRNA-based drugsRNA therapyLipid nanoparticle delivery therapy (as a delivery modality)
Industry: Biotech

Drug pipeline

6 assets

NTX-471

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Nutcracker collaborates with leading medical institutions and clinical investigators but no specific pharma/biotech partners are publicly named

Beyond the preview

Go deeper on Nutcracker Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutcracker Therapeutics.

Explore the full profile